BSMO Annual Meeting 2017

Downloads:

 Programme and abstracts

Slides are available for download here [only presenters which have given permission for online publication].
 

Friday:

Breast cancer Task force

 Biology of young breast cancer and management in pregnant woman - Matteo Lambertini, Institut J. Bordet, Brussels

 Fertility and breast cancerIsabelle Demeestere, ULB, Brussels

Anthracyclines always needed in (neo)adjuvant chemotherapy regimens? - Hans Wildiers, UZ Leuven

Genetic variability and risk of neutropenia – related events and cardiac toxicity - Christof Vulsteke, AZ Maria Middelares, Gent

Quality control on systemic treatment of Breast Cancer - Didier Verhoeven, AZ Klina, Antwerpen

 Update on the neoadjuvant trial of BSMOChristel Fontaine, UZ Brussel

Potential projects for the Breast Task Force Cancer of BSMO - Ahmad Awada, Institut J. Bordet, Brussels
Oncodistinct network and potential collaboration on projects with the BSMO

Central Nervous system

Functional neuroanatomy for the medical oncologist - David Crosiers, UZ Antwerpen

 CNS imagingBert De Foer, Sint-Augustinus, Antwerpen

 NeurosurgeryTony Van Havenbergh, Sint-Augustinus, Antwerpen

 Radiotherapy - Karen Van Beek, UZ Leuven

 CNS disease and systemic treatment optionsNicolas Whenham, UCL

 Leptomeningeal diseasePierre Freres, CHU Liège


Saturday:

Oncology Paper of the year 2016 presentation & award
 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer - Martine Piccart, Institut J. Bordet, Brussel

Proffered papers by junior members

 O.1 Circulating Tumour Cells and Survival in Abiraterone- and Enzalutamidetreated; Patients with Castration-Resistant Prostate CancerBram De Laere, University of Antwerp

 O.2 Immuno-FIELT: The role of Tumor Infiltrating Lymphocytes and PD-L1 expression in NSCLC adenocarcinoma in little to non-smokers and its relationship with driver mutations and clinical outcome parametersSacha Mignon, Vrije Universiteit Brussel

 O.3 Identification of candidate breast cancer predisposition genes by sequencing extended panel of 492 cancer associated genes in BRCA1/2 negative probands - Rajendra Bahadur Shahi, Vrije Universiteit Brussel

O.4 Type II RAF inhibition causes superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer - Amir Noeparast, VUB

O.5 Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial
Laurence Buisseret, Institut J. Bordet, Brussels

 O.7 Mutational Landscaping of Liver Metastases with Desmoplastic and Replacement Growth PatternsPieter-Jan Van Dam, University of Antwerp

 O.8 Evaluation of HER2 expression and amplification in CTCs using CellSearch immunofluorescence and FISHAnja Brouwer, GZA hospitals Sint-Augustinus

O.9 Geriatric assessment (GA)- guided interventions in older patients (pts) with cancer - Lore Decoster, UZ Brussel

O.10 USP13 as a novel co-target for EGFR targeted therapies in EGFR mutant nonsmall cell lung cancer - Philippe Giron, Vrije Universiteit Brussel

Heuson memorial Lecture

 “From a nihilistic point of view to some hope in lung cancer management”Paul Vanhoutte, Institut J. Bordet, Brussels

Sponsored Awards: MSD Oncology Award + Leo Pharma Grant

 What you should not have missed in 2016Luc Dirix, GZA Antwerpen

 

BSMO Annual Meeting 2017

  • Prof De Greve

    Prof De Greve: opening

  • Oncology Paper of the year 2016 presentation & award

    70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer - Martine Piccart, Institut J. Bordet, Brussels

  • Heuson memorial Lecture

    “From a nihilistic point of view to some hope in lung cancer management” - Paul Vanhoutte, Institut J. Bordet, Brussels

  • MSD Award

    MSD Award

    Dr Kurt G. Tournoy, MD PhD

    Implementation of quality indicators to improve the care of the lung cancer patiens

  • MSD Award

    MSD Award

    Dr Kurt G. Tournoy, MD PhD

  • 1st prize oral presentation: Bram De Laere

  • Leo Pharma Award

    Leo Pharma Award

    HAGUET Hélène

    Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

    A Systematic Review and Meta-analysis

  • Leo Pharma Award

    Leo Pharma Award

    HAGUET Hélène

    Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

    A Systematic Review and Meta-analysis

  • Second best oral presentation

    Second best oral presentation:

    Laurence Buisseret

  • Poster winner

    Georges El Hachem, Jules Bordet, Brussels

  • Evandro de Azambuja

  • Hans Prener

  • Evandro de Azambuja and Hans Prenen

  • Peter Vuylsteke